Cancer Biomarker Detection With Luminex Assays
Luminex and Bio-Techne are working together to support the development of early diagnostic solutions that detect cancer earlier through the use of proteomics.
Charles Rosser, a research scientist and professor of biomedical sciences, has developed a multiplex test for early-stage bladder cancer using Luminex® xMAP® Technology. Bladder cancer affects over 570,000 people globally each year, and the Oncuria® test aims to detect bladder cancer, monitors for recurrence, and predicts which patients will benefit from the immunotherapy treatment. Current diagnostic assays lack sensitivity and do not provide a comprehensive view of the cancer’s molecular profile, but the Oncuria® test covers 10 glycoproteins to detect the biological signature of bladder cancer with sensitivity of 90% to 93% and specificity of 86% to 95%. The test received Breakthrough Device Designation status from the FDA and is currently available as a laboratory-developed test (LDT). In a recent clinical validation study involving about 350 patients, the test offered 93% sensitivity. Learn more about this major shift in the care of patients with bladder cancer.
Biomarker Assays Irving Institute for Clinical and Translational Research
Frontiers Comparison of Bead-Based Fluorescence Versus Planar Electrochemiluminescence Multiplex Immunoassays for Measuring Cytokines in Human Plasma
Novel modification of Luminex assay for characterization of extracellular vesicle populations in biofluids
Biomarker Discovery Methods Evolving
Reagents and Assays for Early Cancer Biomarker Discovery
Luminex immunosandwich assay and IP-MS approach.(a) The left panel
A Fixation Protocol Compatible With RD Systems Luminex Assays Enabling Analysis With Infectious Samples
The recent advancements in the early detection of cancer biomarkers by DNAzyme-assisted aptasensors, Journal of Nanobiotechnology
Multiplex Cancer Assays for Cancer Biomarker Detection
Cancer Biomarker Detection With Luminex Assays
Cancers, Free Full-Text